[Childhood asthma and viral infection: interactions and therapeutic possibilities].
Rhinovirus infections are the main cause of wheezing in children and adults. Studies carried out with experimental infections report that at least in certain conditions, this infection may spread to the lower respiratory tract as the virus acts on the respiratory epithelium. In vitro experiments with cells from the immune system and lower respiratory tract suggest that the mechanisms of action are directly linked to the production of pro-inflammatory cytokines. Both in vivo and in vitro evidence shows that rhinoviruses may stimulate bronchial epithelial cells to produce cytokines and pro-inflammatory chemokines. They may also stimulate the cholinergic and non-cholinergic nervous system, increasing the production of ICAM-1 and may give rise to a T-lymphocyte non-specific response or to T-lymphocyte replication in direct relation with viral infection. In addition, greater production of cysteinyl leukotrienes has been observed in the secretions of patients with bronchospasm. Experimental infection with Rhinovirus increases clinical symptomatology and bronchial hyperreactivity. The latter is associated with increased eosinophils and cationic proteins in sputum. The above findings suggest that multiple cellular pathways are involved in the induction of exacerbations of asthma induced by the virus. In addition, the possible stimulating role of exposure to allergens in sensitized patients would also increase allergic inflammation. Because of the limited therapeutic efficacy of steroids in reducing exacerbations, new treatment strategies based on greater insight into the physiopathology of the role of viruses in asthma are needed.
Boquete
M
M
Complexo Hospitalario Xeral-Calde, Sección de Alergia, Lugo.
Carballada
F
F
D000328:Adult; D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000276:immunology; D001249:Asthma / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000378:metabolism; D004311:Double-Blind Method; D004847:Epithelial Cells / Q000378:metabolism / Q000821:virology; D005786:Gene Expression Regulation / Q000187:drug effects; D006633:Histamine Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007223:Infant; D018836:Inflammation Mediators / Q000378:metabolism; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis / Q000235:genetics; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D017336:Loratadine / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D010850:Picornaviridae Infections / Q000150:complications / Q000453:epidemiology / Q000276:immunology; D011323:Primates; D016032:Randomized Controlled Trials as Topic; D012229:Rhinovirus / Q000276:immunology / Q000472:pathogenicity / Q000502:physiology; D013256:Steroids; D016896:Treatment Outcome; D014777:Virus Diseases / Q000150:complications* / Q000453:epidemiology / Q000276:immunology
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000914:Antibodies, Viral; D016207:Cytokines; D006633:Histamine Antagonists; D018836:Inflammation Mediators; D020024:Leukotriene Antagonists; D013256:Steroids; D018799:Intercellular Adhesion Molecule-1; D007073:Immunoglobulin E; D017336:Loratadine